This article delves into the development saga of the Kaveri engine for...
Fundamentals for Suven Pharmaceuticals Limited
Last Updated:
2025-05-29 19:48
Overall Fundamental outlook
Business Operations:
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Revenue projections:
Revenue projections for SUVENPHAR SUVENPHAR's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
currentRatio
0.000000
forwardPE
59.215343
debtToEquity
1.945000
earningsGrowth
0.755000
revenueGrowth
0.397000
grossMargins
0.627760
operatingMargins
0.316950
trailingEps
10.890000
forwardEps
0.000000
SUVENPHAR's forward PE ratio is too high, which may hinder future price growth and increase the risk of a price correction. Investors should carefully evaluate this metric along with other key financial indicators to get a full picture of the stock's potential. SUVENPHAR's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that SUVENPHAR is expected to continue growing, with rising profits and sales contributing to its long-term success. Suven Pharmaceuticals Limited's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
Price projections:
Price projections for SUVENPHAR SUVENPHAR's present price, in comparison to its projections, indicates no evident risks or opportunities. This balanced scenario suggests a steady environment, where investors might choose to wait for more definitive indicators before altering their strategies.
Recommendation changes over time:
Recommendations trend for SUVENPHAR
SUVENPHAR has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view SUVENPHAR as a reliable choice for their money, offering a promising avenue for future growth and financial gains.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
This article analyzes the recently announced 5% remittance tax by the Trump...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.